Diana E. Magee

Diana E. Magee

Auto-generated profile, based on publicly available information

Diana E. Magee

Department of Urology

Research Focus & Metrics

Academic Career Length

7Years (2020-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
23 June 2021 in Cancer
Verified
Journal Article
Closed access
PDF file
KDKyle A. Dymanus
Kyle A. Dymanus
MBMohit Butaney
Mohit Butaney
DMDiana E. Magee
Diana E. Magee
AHAmanda E Hird
Amanda E Hird
ALAmy N. Luckenbaugh
Amy N. Luckenbaugh
CWChristopher Wallis
Christopher Wallis

29 April 2023 in Urologic Oncology: Seminars and Original Investigations
Verified
Journal Article
Closed access
LBLaura Bukavina
Laura Bukavina
SBSpencer Bell
Spencer Bell
VPVignesh T. Packiam
Vignesh T. Packiam
MSMarc Smaldone
Marc Smaldone
PAPhilip Abbosh
Philip Abbosh
DMDiana E. Magee
Diana E. Magee

1 April 2021 in Clinical Genitourinary Cancer
Verified
Journal Article
Closed access
AHAmanda E Hird
Amanda E Hird
DMDiana E. Magee
Diana E. Magee
DCDouglas C. Cheung
Douglas C. Cheung
BSBeate H Sander
Beate H Sander
SSSrikala S. Sridhar
Srikala S. Sridhar
GKGirish S. Kulkarni
Girish S. Kulkarni

9 January 2023 in Current Opinion in Urology
Verified
Journal Article
Closed access
DMDiana E. Magee
Diana E. Magee
EHEmma Helstrom
Emma Helstrom
AKAlexander Kutikov
Alexander Kutikov
Purpose of review: Cytoreductive nephrectomy has had a variable role in the management of metastatic renal cell carcinoma (RCC) through the different systemic therapy eras. Initially felt to be beneficial with interferon, the utility of cytoreductive nephrectomy was called into question in the tyrosine kinase inhibitor (TKI) era. However, with the advent of immunotherapy for metastatic RCC, the role of cytoreductive nephrectomy continues to be debated. This study sought to evaluate the recent literature and discuss cytoreductive nephrectomy within the context of an improved systemic therapy era. Recent findings: The literature that exists on the use of cytoreductive nephrectomy with immunotherapy is retrospective in nature and largely derived from large, institutional databases. Although smaller, single-institution articles exist and provide more granular data, issues concerning selection bias and unmeasured confounders persist. Overall, the available studies demonstrate that patient selection is paramount, and cytoreductive nephrectomy should be reserved for patients with no more than one risk factor, those requiring palliation of local symptoms and for those patients with stable, low volume disease or with a complete response following systemic therapy exposure. Summary: The optimal use of cytoreductive nephrectomy in metastatic RCC remains unclear, but certain subgroups of patients, on evaluation of post hoc and retrospective data, seem to benefit from surgical intervention.

19 April 2021 in Journal of the American College of Surgeons
Verified
Journal Article
Closed access
PDF file
RSRashid K. Sayyid
Rashid K. Sayyid
SLSoum D. Lokeshwar
Soum D. Lokeshwar
ALAmy N. Luckenbaugh
Amy N. Luckenbaugh
MHMary E. Hall
Mary E. Hall
CJCaitlin E. Jones
Caitlin E. Jones
CWChristopher Wallis
Christopher Wallis
BACKGROUND: Female authorship opportunities have lagged behind those of their male counterparts, with gender disparities most prominent in surgical specialties. Our objective was to determine trends of female first, last, and first or last authorships across time and surgical specialties and whether female first or last authorship was associated with journal impact factor. STUDY DESIGN: A systematic review of EMBASE (OvidSP), MEDLINE (OvidSP), and Cochrane (Wiley) databases from inception to December 22, 2017 was performed to identify all randomized controlled trials evaluating minimally invasive surgery vs classical surgical techniques. The primary end point was female first, last, and first or last authorship, with gender determined via an online search strategy and verified via Genderize.io. Secondary end point was journal impact factor, recorded from Clarivate Analytics InCites. RESULTS: There were 9,321 articles identified and 489 met our inclusion/exclusion criteria. Sixty-eight (13.9%) first and 60 (12.3%) last female authors were identified. A positive linear trend for female first (R 2 = 0.35, Cochran-Armitage test for trend, p < 0.001), last (R 2 = 0.30, p < 0.001), and first or last authorships (R 2 = 0.40, p < 0.001) over time was identified. This trend was observed across surgical specialties except for orthopaedics. The highest calculated percentages of female first, last, and first or last authorships by the year 2017 were seen in obstetrics and gynecology (33.8%, 32.0%, and 43.8%, respectively), all significantly lower than the corresponding percentage of the female obstetrics and gynecology workforce in 2017 (57.0%). Neither female first nor last authorship positions were associated with journal impact factor. CONCLUSIONS: A significant increase in female first and last authorship in randomized controlled trials of minimally invasive surgical techniques in the last 3 decades has been observed, but continued efforts to bridge this gender gap are sorely needed.

1 March 2022 in European Urology
Verified
Journal Article
Closed access
DMDiana E. Magee
Diana E. Magee
AKAlexander Kutikov
Alexander Kutikov